Phase I clinical study of orally-dosed HBW-3220 in patients with relapsed/refractory B-cell lymphoma
Conferences
- Overview
- Research
- Additional Document Info
- View All
Overview
status
publication date
- June 1, 2023
has subject area
- 1103 Clinical Sciences (FoR)
- 1112 Oncology and Carcinogenesis (FoR)
- Oncology & Carcinogenesis (Science Metrix)
published in
- Journal of Clinical Oncology Journal